Keros Therapeutics, Inc. — Director's Dealing 2021

Jun 3, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Keros Therapeutics, Inc. (KROS)
CIK: 0001664710
Period of Report: 2021-06-01

Reporting Person: Farzan Nima (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-06-01	Stock Option (right to buy)	$51.48	A	8293	Acquired	2031-05-31	Common Stock (8293)	Direct

Footnotes

F1: The option shall vest in equal quarterly installments over the 12 months following the date of grant, provided that the grant will in any case be
fully vested on the date of Issuer's 2022 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through
each such date.